Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer.

Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer. J Clin Oncol. 2002 Mar 15; 20(6):1519-26.

View in: PubMed

subject areas

Administration, Oral
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
Colorectal Neoplasms
Disease Progression
Drug Administration Schedule
Drug Synergism
Female
Fluorouracil
Humans
Infusions, Intravenous
Leucovorin
Male
Middle Aged
Neoplasm Metastasis
Proportional Hazards Models
Survival Analysis
Treatment Outcome
Uracil

authors with profiles

Richard Schilsky